On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck ...

Bio-Techne TECH reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of 56 cents, which surpassed the Zacks Consensus Estimate by 9.8%. The bottom line improved from the year-ago ...

According to a Feb. 17, 2026, SEC filing, Hollow Brook Wealth Management LLC sold out its entire position in Bio-Techne (NASDAQ:TECH) during the fourth quarter of 2025. The fund divested 174,677 ...

Bio-Techne’s (TECH Quick Quote TECH - Free Report) GMP reagents, including GMP proteins and small molecules, remain a cornerstone of its cell therapy offering. Acquisitions have continued to play an ...

Valued at a market cap of $9.3 billion, Bio-Techne Corporation (TECH) is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities.

Merck will buy Minneapolis-based Bio-Techne Corp. in a deal worth $11.3 billion. Bio-Techne was under pressure from an ...

(TECH) was up 20.9% in pre-market trading, and Micron Technology Inc. (MU) was up 17.7%.